This site is intended for healthcare professionals
News

FDA grants priority review to KTE X 19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. Kite/Gilead.

Read time: 1 mins
Published:11th Feb 2020
Kite, a Gilead Company announced that the FDA has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The BLA is supported by data from the single arm, open-label, Phase II ZUMA-2 trial, which showed that 93 percent of patients responded to a single infusion of KTE X19, including 67 percent of patients achieving a complete response, as assessed by an Independent Radiologic Review Committee (IRRC; median follow-up of 12.3 months). In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented during an oral session at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando.
Condition: Mantle Cell Lymphoma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.